Here’s the latest CBD News:
Proposed by Senator Chuck Schumer (D-NY) on Wednesday (Jul 14), the Cannabis Administration and Opportunity Act seeks to regulate the sale of CBD (and high-THC marijuana) so that users and sellers in legal states would not be penalized on a federal level.
Per the draft language, the bill would remove cannabis from the Controlled Substances Act, effectively decriminalizing non-violent crimes involving marijuana.
This legislation would also include CBD in the definition of a dietary supplement by amending section 201(ff)(3)(B) of the Federal Food, Drug, and Cosmetic Act (which explicitly excludes THC and CBD from said definition).
Another CBD-related provision proposed in the bill aims to define and enforce a CBD content threshold for product safety.
Finally, the bill outlines the CBD regulation process for the FDA, should this draft be enacted into law.
Most cannabis-related studies and reports focusing on the synergistic action of terpenes within the plant have had to take a speculative stance, but thanks to this study from the University of Arizona, the “entourage effect” has been confirmed more concretely.
Entitled “Cannabis Sativa Terpenes Are Cannabimimetic and Selectively Enhance Cannabinoid Activity,” the experimenters in the study tested the effects of terpenes on mice in two scenarios: terpenes only and terpenes administered with a cannabinoid agonist.
The researchers found that the terpenes alpha-humulene, geraniol, linalool, and beta-pinene “produced cannabinoid tetrad behaviors in mice, suggesting cannabimimetic activity.”
In other words, even without THC or CBD, terpenes are able to mimic their effects by interacting with the body in similar ways.
On Tuesday (Jul 13), Biotech Manufacturer Catalent announced that they had entered into a product development deal with JOS Pharmaceuticals, a biopharmaceutical company that specializes in anesthesiology.
As stipulated in the agreement, Catalent will perform a feasibility study to pave the way for the licensing of a CBD-based “anesthetic premedication” developed by JOS Pharmaceuticals.
The medication will be delivered via an “orally disintegrating tablet (ODT)” developed by Catalent, and JOS Pharmaceuticals will provide the CBD-based sedation anesthesia product, which they’ve named se•d8™.
The product is intended to keep patients awake, but relaxed so they can more comfortably undergo various procedures.